CIL005 and CIL006 extend the French biotech’s portfolio into cochlear inflammation and oxidative stress, targeting new patient populations beyond its lead cochlear synaptopathy program. Cilcare , a Montpellier, France-based biopharmaceutical company focused on auditory science, has announced two new exclusive licensing agreements with Sanofi for therapeutic assets designated CIL005 and CIL006....
Continue reading at Hearing Review
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is an early-stage pipeline licensing announcement with no clinical trial data reported.
If successful in development, these licensed compounds could broaden the range of biological targets being pursued for inner-ear drug therapy, potentially offering future treatment options beyond current hearing aids and cochlear implants.
- 01Cilcare licensed two compounds, CIL005 and CIL006, exclusively from Sanofi.
- 02CIL005 targets cochlear inflammation; CIL006 targets oxidative stress in the inner ear.
- 03Both compounds expand Cilcare's pipeline beyond its lead cochlear synaptopathy program.
- 04No clinical trial data or timelines were disclosed in the announcement.
- 05Deal reflects growing pharma interest in inner-ear biologics and drug repurposing.
CIL005 targets cochlear inflammation as a therapeutic mechanism.
press releaseunclearCIL006 targets oxidative stress in the cochlea as a therapeutic mechanism.
press releaseunclearThe licensing agreements are exclusive, granting Cilcare sole rights to develop the compounds.
press releasesupported